FDA Warning Letters Hit Inadequate Investigations and QC Failings
This article was originally published in The Gold Sheet
Executive Summary
In recent warning letters, FDA continued to hammer manufacturers for inadequate investigation of out-of-specification results and lax oversight of manufacturing operations by quality control units.
You may also be interested in...
Enforcement Updates in Brief
Pan Drugs told FDA it would divert dirty plant’s API to India; Zhejiang Hisun reels from import alert, warning letter; Impax resolves warning letter; Polydrug and Akorn put on import alert; and TxCell outsources GMP problems away.
FDA Drug GMP Warning Letters Increase 6%, Focus on Supply Chain and Sterility Assurance in FY 2011
The number of drug GMP warning letters issued by FDA continued to climb in fiscal year 2011, with supply chain and sterility assurance issues dominating the agency’s attention. FDA is requesting a budget increase in FY 2013 to expand its inspectional presence abroad to better meet global supply chain threats, and agency officials are saying that failure to monitor contract manufacturers is a major problem shown in recent warning letters, but that failure to investigate out-of-specification results is still the No. 1 finding.
Dr. Reddy’s Gets U.S. FDA Advertising Letter, But Its Response Is Far From Generic
Despite changes to the website, the boxed warning about the risk of epidural or spinal hematomas for patients taking generic fondaparinux still receives little emphasis on a Dr. Reddy’s promotional page.